# Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Source: https://onco.cc/trials/nct06470451/  
OnCo record `nct06470451` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Synthetic hypericin in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by Soligenix, recorded as terminated on the registry.

## Summary

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL is a phase 3 interventional study registered as NCT06470451 by Soligenix, with 70 participants recorded, started 2025-01-07 and due to reach its primary completion in 2026-05-22. Interventions recorded: Hypericin, Placebo. Conditions recorded: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma.

Linked to the drug Synthetic hypericin because the registry names it among its interventions and Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06470451
- Phase: 3
- Setting: A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
- Sponsor: Soligenix
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06470451: https://clinicaltrials.gov/study/NCT06470451

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Synthetic hypericin](https://onco.cc/drugs/hypericin-sgx301/)
- companies: [Soligenix](https://onco.cc/companies/soligenix/)

---
JSON: https://onco.cc/api/v1/entities/nct06470451.json